BIOMAT Database Logo BIOMAT Database Logo

Meningococcal C polysaccharide vaccine induces immunologic hyporesponsiveness in adults that is overcome by meningococcal C conjugate vaccine. 2000

P Richmond, and E Kaczmarski, and R Borrow, and J Findlow, and S Clark, and R McCann, and J Hill, and M Barker, and E Miller
Immunisation Division, Communicable Disease Surveillance Centre, Public Health Laboratory Service, Immunobiology Unit, Institute of Child Health, London, United Kingdom.

Widespread use of meningococcal AC polysaccharide (MACP) vaccines has raised concerns about induction of hyporesponsiveness to C polysaccharide. Whether meningococcal C conjugate (MCC) vaccine overcomes any immunologic refractoriness following MACP vaccination in adults was investigated. University students vaccinated 6 months previously with MACP vaccine were randomized to receive MACP or MCC vaccine, and antibody responses were compared with those of previously unvaccinated students receiving MACP or MCC vaccine. In students primed with MACP vaccine, MCC vaccine induced significantly higher IgG and serum bactericidal antibody levels than did a second dose of MACP vaccine. Responses to a second dose of MACP vaccine were significantly lower than to the first dose. Previous receipt of MACP vaccine reduced serum bactericidal antibody but not IgG responses to MCC vaccine compared with those in previously unvaccinated students. This confirms that MACP vaccine induces immunologic hyporesponsiveness to C polysaccharide in adults, but this can be overcome with MCC vaccine. Repeated vaccination with MACP vaccine may be ineffective, and MCC vaccines should provide better long-term protection.

UI MeSH Term Description Entries
D007117 Immunization, Secondary Any immunization following a primary immunization and involving exposure to the same or a closely related antigen. Immunization, Booster,Revaccination,Secondary Immunization,Booster Immunization,Booster Immunizations,Immunizations, Booster,Immunizations, Secondary,Revaccinations,Secondary Immunizations
D008297 Male Males
D009345 Neisseria meningitidis A species of gram-negative, aerobic BACTERIA. It is a commensal and pathogen only of humans, and can be carried asymptomatically in the NASOPHARYNX. When found in cerebrospinal fluid it is the causative agent of cerebrospinal meningitis (MENINGITIS, MENINGOCOCCAL). It is also found in venereal discharges and blood. There are at least 13 serogroups based on antigenic differences in the capsular polysaccharides; the ones causing most meningitis infections being A, B, C, Y, and W-135. Each serogroup can be further classified by serotype, serosubtype, and immunotype. Diplokokkus intracellularis meningitidis,Meningococcus,Micrococcus intracellularis,Micrococcus meningitidis,Micrococcus meningitidis cerebrospinalis,Neisseria weichselbaumii
D011135 Polysaccharides, Bacterial Polysaccharides found in bacteria and in capsules thereof. Bacterial Polysaccharides
D005260 Female Females
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000293 Adolescent A person 13 to 18 years of age. Adolescence,Youth,Adolescents,Adolescents, Female,Adolescents, Male,Teenagers,Teens,Adolescent, Female,Adolescent, Male,Female Adolescent,Female Adolescents,Male Adolescent,Male Adolescents,Teen,Teenager,Youths
D000328 Adult A person having attained full growth or maturity. Adults are of 19 through 44 years of age. For a person between 19 and 24 years of age, YOUNG ADULT is available. Adults
D000907 Antibodies, Bacterial Immunoglobulins produced in a response to BACTERIAL ANTIGENS. Bacterial Antibodies
D001428 Bacterial Vaccines Suspensions of attenuated or killed bacteria administered for the prevention or treatment of infectious bacterial disease. Bacterial Vaccine,Bacterin,Vaccine, Bacterial,Vaccines, Bacterial

Related Publications

P Richmond, and E Kaczmarski, and R Borrow, and J Findlow, and S Clark, and R McCann, and J Hill, and M Barker, and E Miller
Meningococcal C polysaccharide vaccine induces immunologic hyporesponsiveness in adults: additional data.
July 2001, The Journal of infectious diseases,
P Richmond, and E Kaczmarski, and R Borrow, and J Findlow, and S Clark, and R McCann, and J Hill, and M Barker, and E Miller
Can meningococcal C conjugate vaccine overcome immune hyporesponsiveness induced by previous administration of plain polysaccharide vaccine?
April 2000, JAMA,
P Richmond, and E Kaczmarski, and R Borrow, and J Findlow, and S Clark, and R McCann, and J Hill, and M Barker, and E Miller
Immunologic hyporesponsiveness in man to group C meningococcal polysaccharide.
July 1975, Journal of immunology (Baltimore, Md. : 1950),
P Richmond, and E Kaczmarski, and R Borrow, and J Findlow, and S Clark, and R McCann, and J Hill, and M Barker, and E Miller
Safety and immunogenicity of meningococcal A and C polysaccharide conjugate vaccine in adults.
August 1994, Infection and immunity,
P Richmond, and E Kaczmarski, and R Borrow, and J Findlow, and S Clark, and R McCann, and J Hill, and M Barker, and E Miller
Conjugate versus polysaccharide meningococcal vaccine.
April 2008, The Lancet. Infectious diseases,
P Richmond, and E Kaczmarski, and R Borrow, and J Findlow, and S Clark, and R McCann, and J Hill, and M Barker, and E Miller
Induction of immunologic refractoriness in adults by meningococcal C polysaccharide vaccination.
September 1998, The Journal of infectious diseases,
P Richmond, and E Kaczmarski, and R Borrow, and J Findlow, and S Clark, and R McCann, and J Hill, and M Barker, and E Miller
Priming for immunologic memory in adults by meningococcal group C conjugate vaccination.
June 2006, Clinical and vaccine immunology : CVI,
P Richmond, and E Kaczmarski, and R Borrow, and J Findlow, and S Clark, and R McCann, and J Hill, and M Barker, and E Miller
Vaccine potential of meningococcal group C polysaccharide-tetanus toxoid conjugate.
May 1983, The Journal of infection,
P Richmond, and E Kaczmarski, and R Borrow, and J Findlow, and S Clark, and R McCann, and J Hill, and M Barker, and E Miller
Prior meningococcal A/C polysaccharide vaccine does not reduce immune responses to conjugate vaccine in young adults.
November 2002, Vaccine,
P Richmond, and E Kaczmarski, and R Borrow, and J Findlow, and S Clark, and R McCann, and J Hill, and M Barker, and E Miller
Comparison of antibody kinetics following meningococcal serogroup C conjugate vaccine between healthy adults previously vaccinated with meningococcal A/C polysaccharide vaccine and vaccine-naïve controls.
April 2001, Vaccine,
Copied contents to your clipboard!